CD14 Efficacy of narrowband ultraviolet B phototherapy vs. low-dose oral ciclosporin as second-line management in antihistamine-refractory chronic spontaneous urticaria: a noninferiority, randomized study

N Roshini,Hitaishi Mehta,Anuradha Bishnoi,Davinder Parsad,Sendhil Kumaran
DOI: https://doi.org/10.1093/bjd/ljae090.193
IF: 11.113
2024-06-28
British Journal of Dermatology
Abstract:Abstract Literature regarding the role of narrowband ultraviolet B (NB-UVB) phototherapy in the treatment of antihistamine-resistant chronic spontaneous urticaria (CSU) is scarce, and ciclosporin has established its role in management. We aimed to study the efficacy of NB-UVB phototherapy vs. low-dose oral ciclosporin in the management of chronic refractory urticaria (CRU), terms of change in Urticaria Activity Score (UAS), Urticaria Control Test (UCT), Chronic Urticaria Quality of Life (CU-QoL) and Angioedema Activity Score (AAS). In this randomized prospective noninferiority study, 50 patients were recruited who fulfilled the criteria of oral antihistamine-refractory CSU, namely 6 months of spontaneous urticaria with no response from three consecutive months of antihistamines, and steroid dependence. The patients were randomized to receive NB-UVB (group A) or ciclosporin 3 mg kg−1 (group B) for 90 days, with post-treatment follow-up of 90 more days. Patients were assessed fortnightly. The mean (SD) UAS7 decreased from baseline scores of 24.8 (8.2) and 27.1 (8.2) to 0.82 (1.47) and 0.28 (1.4) in group A and group B, respectively at the end of the 90-day treatment (P < 0.001). These increased to 1.55 (1.74) and 4.13 (4.85) at day 180 in groups A and B, respectively (P = 0.01 and P = 0.002). The mean (SD) UCT scores increased from baseline 8.52 (2.8) and 8.24 (2.67) to 15.0 (1.7) and 15.9 (0.4) at day 90 (P < 0.001), which decreased to 14.9 (1.0) and 14.1 (2.0) at day 180 in groups A and B, respectively (P = 0.03 and P = 0.001). The mean (SD) CU-QoL decreased from baseline scores of 26.8 (14.9) and 30.0 (14.9) to 3.4 (6.3) and 0.48 (2.0) at day 90 (P < 0.001 and P = 0.002), which increased to 2.1 (2.3) and 4.9 (5.2) at day 180 in groups A and B, respectively (P = 0.09 and P = 0.001). The mean (SD) AAS7 scores decreased from baseline 2.0 (4.7) and 4.9 (8.2) to 0 (0) and 0 (0) at day 90 in both groups (P = 0.04 and P = 0.007). AAS7 scores remained at 0 through follow-up. Ciclosporin performed as a crisis buster, giving early and better control of CRU during the treatment period; however, disease relapsed promptly on stopping ciclosporin. On the other hand NB-UVB had more sustained suppression of CRU even during follow-up. Thus NB-UVB is an effective, safe, affordable therapeutic modality for steroid-dependent CRU. Our study had a small sample size and the results may not be representative of a bigger population.
dermatology
What problem does this paper attempt to address?